



The Incyte Grant for Hematological Research

Grant Review Committee Governance Charter

Purpose

The Incyte Grant for Hematological Research is intended to stimulate the interest for research in the field of hematological malignancies and to encourage young clinicians/researchers to participate in scientific advancement by supporting the realization of high quality research and development projects.

Funding

It is intended that one or more unrestricted grants of up to 40,000 USD will be awarded annually, funded by Incyte Biosciences Nordic AB. The grant is awarded once per year. Each year, an assessment will be conducted and a decision to continue the funding of the Grant will be made by Incyte in consultation with the Grant Review Committee.

Applicants and application

Preclinical and clinical projects within malignant hematology are eligible, with a priority on projects focusing on leukemia/lymphoma.

Eligible applicants for the Grant are researchers active at a Nordic unit and performing research primarily taking place in the Nordic region. Priority will be given to applicants scheduled to present their dissertation within the next 18 months or has done so no more than three (3) years ago.

Applications should contain a rationale and background of the project, the objectives, a description of methodology, defined timelines and a specified budget (with detailed budget cost breakdown).

Applications will be subject to the terms and conditions contained in the Attachment to this Charter.





Grant Review Committee

The Grant Review Committee consists of professor Magnus Björkholm, chairman (Karolinska Institute – Sweden), professor Kari Remes (Turku University – Finland), Harald Holte, MD, PhD (Oslo University – Norway) and the Medical Director of Incyte Biosciences Nordic AB, the latter without voting rights.

The Grant Review Committee will select the Project which will receive the Grant funding. Decisions will be made based on majority voting. In case of a tie, the Committee chairman will cast the decisive vote.

Announcement of the winner(s) will be made before the end of the year and potentially advertised through trade media.

Commitment

The intent is to award full or partial funding for one or more projects. However the total maximum funding amount shall not exceed 40.000 USD.

The Committee also reserves the right to hand out parts or none of the funding budget.

The recipient (or recipients) of the Grant commits to report to the Committee upon completion of the project. Within one (1) year from the receipt of the funds, an interim report is to be submitted to the Committee.

Transparency Disclosure

A transparency disclosure – “This Project was supported by an unrestricted educational grant by Incyte Biosciences Pharmaceuticals” – will be included in project communications and publications.

Application Submission

Applications, maximum four (4) pages plus one (1) CV page, all together five (5) pages, should be sent as an electronic version to: thenordicgrant@incyte.com

And one (1) paper copy addressed to:

**Incyte Grant for Hematological
Research**
c/o Incyte Biosciences Nordic AB
Barnhusgatan 3,
111 23 Stockholm
Sweden

Deadline

Applications must be submitted by the 1st of October 2024 to be considered for the 2024 Grant.



Announcements

The recipient (or recipients) of the Grant will be notified in writing before the end of the year. Incyte may publish communications (e.g. trade media) about the Grant (including the application process and the final outcome). Details on membership of the Grant Committee may be disclosed in such communications.

On behalf of the Incyte Grant for Hematological Research Review Committee

Professor Magnus Björkholm, Chairman

Karolinska Institute, Sweden

Professor Kari Remes

Turku University, Finland

Harald Holte, MD, PhD

Oslo University, Norway

Julie Bekaert

Incyte Biosciences, Senior Medical Director, Nordics

Attachment 1

Grant Application Terms and Conditions

Purpose

The Incyte Grant for Hematological Research is intended to stimulate the interest for research in the field of hematological malignancies and to encourage young clinicians/researchers to participate in the scientific advancement by supporting the realization of high quality research and development projects.

The following terms and conditions apply to applications submitted for consideration to receive the Incyte Grant for Hematological Research. By submitting an application, applicant agrees to be bound by these terms and conditions.

Applications should be sent as an electronic version to: **thenordicgrant@incyte.com**

And one (1) paper copy addressed to:

**Incyte Grant for Hematological
Research
c/o Incyte Biosciences Nordic AB
Barnhusgatan 3
111 23 Stockholm
Sweden**

1. Applications received after the 1st of October 2024 will not be considered for the 2024 Grant.
2. Applications should contain a rationale and background of the project, the objectives, a description of methodology, defined timelines and a specified budget (with detailed budget cost breakdown). Max. 4 pages plus one CV page.
3. One or more projects may be fully or partially funded, but only up to a total of 40.000 USD.
4. The total Grant funding amount of 40.000 USD may be split between one or more projects.
5. Grant funding will be limited to actual project costs (per budget breakdown included with application submission).
6. The following projects will be considered as eligible: preclinical and clinical projects within malignant hematology with a priority for projects focusing on leukemia/lymphoma.
7. Eligible applicants for the Grant are researchers active at a Nordic unit and performing research primarily taking place in the Nordic region. Priority will be given to applicants scheduled to present their dissertation within the next 18 months or has done so no more than three years ago.
8. Submissions will be reviewed by a Grant Review Committee consisting of professor Magnus Björkholm (Karolinska Institute – Sweden), professor Kari Remes (Turku University – Finland), Harald Holte, MD, PhD (Oslo University – Norway) and the Medical Director of Incyte Biosciences Nordic AB, the latter without voting rights.
9. The decision on the award of the Grant will be made by the Grant Review Committee. Such decision is final and binding.
10. Incyte Biosciences Nordic AB and the Grant Review Committee members may retain a copy of the submitted applications. Submissions will not be returned to applicants.
11. The applicant's name and address and a short summary of the project (based on the application) may be publicly communicated/published by Incyte and/or the Grant Review Committee.
12. The Grant funding will be transferred to a bank account of the institution at which the project will be performed and with which the applicant is affiliated (no payments to personal bank accounts). An assessment of each project and recipient according to national regulations will be made.
13. Accurate and detailed accounting of use of funds must be kept by recipient and reported to the Grant Committee upon conclusion of the project, or upon request at any time.
14. Funding may only be used for legitimate and necessary out-of-pocket costs associated with proper conduct of the project.
15. Unused funds at the end of the project must be refunded to Incyte.
16. No portion of funds to be used to make payments to third parties except as fair market value compensation for legitimate work directly related to the conduct of the project.
17. A transparency disclosure – "This Project was supported by an unrestricted educational Grant by Incyte Biosciences" – will be included in project communications and publications.

The recipient of the Grant commits to report to the Grant Review Committee upon completion of the project. Within one (1) year from the receipt of the funds, an interim report is to be submitted to the Committee.

